3311 - 3320 of 8137 Results
Title
Year
-
OPENTitle: Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body DementiasJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 96Issue #: 14Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000011699Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105963Citation Count: 41
-
OPENTitle: Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegiaJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 8Issue #: 5Start Page: 1122End Page: 1131Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.51358Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.51358Citation Count: 12
- Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis2021RESTRICTEDTitle: Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐AnalysisJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 6Start Page: 1293End Page: 1307Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28599Best OA location URL: https://repository.ubn.ru.nl//bitstream/handle/2066/238481/238481.pdfCitation Count: 20
-
RESTRICTEDTitle: ATP1A3-Related Disorders: An Ever-Expanding Clinical SpectrumJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 12Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2021.637890Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2021.637890/pdfCitation Count: 32
-
OPENTitle: Cerebello‐Cortical Control of Tremor Rhythm and Amplitude in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 7Start Page: 1727End Page: 1729Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28603Best OA location URL: https://repository.ubn.ru.nl//bitstream/handle/2066/238510/238510.pdfCitation Count: 30
-
OPENTitle: Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single‐particle analysis platformsJournal Name: Journal of Extracellular VesiclesPublisher: WileyVol: 10Issue #: 6Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/jev2.12079Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jev2.12079Citation Count: 139
- Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments2021RESTRICTEDTitle: Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New TreatmentsJournal Name: Archives of Medical ResearchPublisher: Elsevier BVVol: 52Issue #: 3Start Page: 243End Page: 251Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.arcmed.2020.10.021Citation Count: 25
-
RESTRICTEDTitle: Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysisJournal Name: CancerPublisher: WileyVol: 127Issue #: 14Start Page: 2409End Page: 2422Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/cncr.33516Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.33516Citation Count: 75
-
OPENTitle: Evidence forGRNconnecting multiple neurodegenerative diseasesJournal Name: Brain CommunicationsPublisher: Oxford University Press (OUP)Vol: 3Issue #: 2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1093/braincomms/fcab095Best OA location URL: https://academic.oup.com/braincomms/article-pdf/3/2/fcab095/41728465/fcab095.pdfCitation Count: 33
-
OPENTitle: Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO TrialJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 7Start Page: 1704End Page: 1711Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.28569Best OA location URL: https://repositorio.uca.edu.ar/bitstream/123456789/11645/6/fluoxetine-symptomatic-treatment-atrophy%20%281%29.pdfCitation Count: 20